论文部分内容阅读
目的:分析西酞普兰联合米氮平对抑郁症患者睡眠障碍的治疗效果.方法:选择2020年2月～2021年2月期间收治的抑郁症合并睡眠障碍患者共70例,以便利抽样法分组,对照组35例,研究组35例.对照组单用西酞普兰,研究组联用西酞普兰与米氮平.组间对比如下指标:(1)不良反应发生率;(2)治疗前后的抑郁评分、睡眠质量评分.结果:研究组不良反应发生率(8.57％)与对照组(14.29％)相近,统计学对比无差异(P＞0.05).治疗前,两组的抑郁评分和睡眠质量评分相近,统计学对比无差异(P＞0.05);治疗后,两组的抑郁评分和睡眠质量评分均较治疗前有所降低且研究组抑郁评分睡眠质量评分均低于对照组,统计学对比有差异(P＜0.05).结论:西酞普兰联合米氮平治疗抑郁症合并睡眠障碍,不仅可以显著改善患者睡眠治疗和抑郁症病情,还有较高的安全性.“,”Objective: to analyze the therapeutic effect of citalopram and mirtazapine on sleep disorders in depression patients. Methods: 70 patients with depression and sleep disorder were selected from February 2020 to February 2021. The patients were divided into three groups by convenient sampling method, 35 in the control group and 35 in the study group. The control group was used citalopram alone, and the study group was combined with citalopram and mirtazapine. The results showed that: (1) the incidence of adverse reactions( 2) The depression score and sleep quality score before and after treatment. Results: the incidence of adverse reactions in the study group was similar to that of the control group (14.29％), and there was no difference in statistical comparison (P ＞ 0.05). Before treatment, the depression score and sleep quality score of the two groups were similar, and there was no difference between the two groups (P ＞ 0.05); After treatment, the scores of depression and sleep quality in both groups were lower than before treatment, and the sleep quality score of the study group was lower than that of the control group (P ＜ 0.05). Conclusion: citalopram combined with mirtazapine in the treatment of depression with sleep disorders can not only improve the sleep treatment and depression, but also have a higher safety.